JP2009524419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009524419A5 JP2009524419A5 JP2008551732A JP2008551732A JP2009524419A5 JP 2009524419 A5 JP2009524419 A5 JP 2009524419A5 JP 2008551732 A JP2008551732 A JP 2008551732A JP 2008551732 A JP2008551732 A JP 2008551732A JP 2009524419 A5 JP2009524419 A5 JP 2009524419A5
- Authority
- JP
- Japan
- Prior art keywords
- lna
- double
- stranded oligonucleotide
- strand
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 19
- 239000000178 monomer Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 5
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- -1 methoxyethyl Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76292006P | 2006-01-27 | 2006-01-27 | |
| PCT/EP2007/000741 WO2007085485A2 (en) | 2006-01-27 | 2007-01-29 | Lna modified phosphorothiolated oligonucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009524419A JP2009524419A (ja) | 2009-07-02 |
| JP2009524419A5 true JP2009524419A5 (enExample) | 2010-03-11 |
Family
ID=38007090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551732A Pending JP2009524419A (ja) | 2006-01-27 | 2007-01-29 | Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090176977A1 (enExample) |
| EP (1) | EP1984382B1 (enExample) |
| JP (1) | JP2009524419A (enExample) |
| AU (1) | AU2007209481B2 (enExample) |
| CA (1) | CA2638837A1 (enExample) |
| DK (1) | DK1984382T3 (enExample) |
| WO (1) | WO2007085485A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004221760B2 (en) | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
| WO2005073378A1 (en) * | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
| ES2556128T3 (es) * | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| JP5723154B2 (ja) | 2007-09-19 | 2015-05-27 | アプライド バイオシステムズ リミテッド ライアビリティー カンパニー | ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型 |
| JP2010539961A (ja) * | 2007-10-04 | 2010-12-24 | サンタリス ファーマ アー／エス | ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物 |
| ES2609655T3 (es) | 2009-05-06 | 2017-04-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP |
| US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| EP3214174B1 (en) | 2010-03-04 | 2019-10-16 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
| EP2591106A1 (en) | 2010-07-06 | 2013-05-15 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| US20140323557A1 (en) * | 2011-11-11 | 2014-10-30 | Santaris Pharma A/S | Compounds for the modulation of beta-catenin expression and uses thereof |
| EP3369818B1 (en) | 2011-12-22 | 2021-06-09 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
| US10201556B2 (en) | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| WO2014140856A2 (en) | 2013-03-15 | 2014-09-18 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
| AU2014306271A1 (en) | 2013-08-08 | 2016-03-24 | The Scripps Research Institute | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
| EP3129493B1 (en) | 2014-04-09 | 2021-07-07 | The Scripps Research Institute | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| US20170369872A1 (en) * | 2014-12-18 | 2017-12-28 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| EP3181698A1 (en) | 2015-12-16 | 2017-06-21 | European Molecular Biology Laboratory (EMBL) | Microrna mir-142 as stem cell marker |
| TWI821192B (zh) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| AU2018358016A1 (en) | 2017-11-03 | 2020-05-07 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| WO2019155094A1 (en) | 2018-02-12 | 2019-08-15 | Interna Technologies B.V. | Anticancer microrna and lipid formulations thereof |
| EP3802824A1 (en) | 2018-06-05 | 2021-04-14 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| BR112021001756A2 (pt) * | 2018-07-31 | 2021-05-11 | Roche Innovation Center Copenhagen A/S | oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| JP7725370B2 (ja) | 2019-04-03 | 2025-08-19 | ブリストル－マイヤーズ スクイブ カンパニー | Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 |
| CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7634542B2 (ja) | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| EP4081639A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| EP4081217A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| CN115551519A (zh) | 2020-05-11 | 2022-12-30 | 基因泰克公司 | 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法 |
| CN115605592A (zh) | 2020-05-11 | 2023-01-13 | 基因泰克公司（Us） | 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法 |
| CN115698290A (zh) | 2020-05-11 | 2023-02-03 | 基因泰克公司 | 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法 |
| JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 |
| EP4259642A1 (en) * | 2020-12-08 | 2023-10-18 | F. Hoffmann-La Roche AG | Novel synthesis of phosphorodithioate oligonucleotides |
| AU2022384619A1 (en) | 2021-11-11 | 2024-04-11 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| CN119095603A (zh) | 2021-12-17 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 用于调节rtel1和fubp1的寡核苷酸的组合 |
| WO2025235462A1 (en) * | 2024-05-06 | 2025-11-13 | Gt Molecular, Inc. | Selective blocking to detect and amplify low abundant template |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2001048190A2 (en) * | 1999-12-23 | 2001-07-05 | Exiqon A/S | Therapeutic uses of lna-modified oligonucleotides |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| EP1478656B1 (en) * | 2002-02-01 | 2009-09-16 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| EP1857547B2 (en) * | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Further novel forms of interfering RNA molecules |
| AU2004221760B2 (en) * | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
| WO2005073378A1 (en) * | 2004-01-30 | 2005-08-11 | Santaris Pharma A/S | MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA) |
| BRPI0515726A8 (pt) * | 2004-11-09 | 2017-09-12 | Santaris Pharma As | Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a |
| ES2556128T3 (es) * | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
-
2007
- 2007-01-29 WO PCT/EP2007/000741 patent/WO2007085485A2/en not_active Ceased
- 2007-01-29 EP EP07711406A patent/EP1984382B1/en not_active Not-in-force
- 2007-01-29 US US12/162,142 patent/US20090176977A1/en not_active Abandoned
- 2007-01-29 CA CA002638837A patent/CA2638837A1/en not_active Abandoned
- 2007-01-29 DK DK07711406.4T patent/DK1984382T3/da active
- 2007-01-29 AU AU2007209481A patent/AU2007209481B2/en not_active Ceased
- 2007-01-29 JP JP2008551732A patent/JP2009524419A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013324716B2 (en) | Oligomers with improved off-target profile | |
| JP2009532392A5 (enExample) | ||
| Watts | Locked nucleic acid: tighter is different | |
| JP2008283975A5 (enExample) | ||
| JP2010512747A5 (enExample) | ||
| FI4220360T3 (fi) | Oligonukleotideja paternaalisen ube3a:n ilmentämiseksi | |
| Pasternak et al. | Unlocked nucleic acid–an RNA modification with broad potential | |
| JP2014527401A5 (enExample) | ||
| JP2019503394A5 (enExample) | ||
| JP2005517432A5 (enExample) | ||
| JP2018507711A5 (enExample) | ||
| JP2009532044A5 (enExample) | ||
| EA200870402A1 (ru) | Фармацевтическая композиция | |
| CA2385853A1 (en) | Design of high affinity rnase h recruiting oligonucleotide | |
| NZ599237A (en) | Sirna compounds comprising terminal substitutions | |
| JP2007529224A5 (enExample) | ||
| JP2003520811A5 (enExample) | ||
| JP2009060893A5 (enExample) | ||
| WO2008074328A2 (en) | Microrna target site blocking oligos and uses thereof | |
| TWI455944B (zh) | 雙股多核苷酸 | |
| JP2015523853A5 (enExample) | ||
| WO2007085485A3 (en) | Lna modified phosphorothiolated oligonucleotides | |
| JP2005517436A5 (enExample) | ||
| JP7033591B2 (ja) | 治療用オリゴヌクレオチドの捕捉および検出 | |
| FI3717646T3 (fi) | Angelmanin oireyhtymän antisense-hoito |